Kathy Triantafilou1, Dilan Eryilmazlar1, Martha Triantafilou2. 1. Institute of Infection and Immunity, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, Wales, UK. 2. Institute of Infection and Immunity, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, Wales, UK. Electronic address: TriantafilouM@cardiff.ac.uk.
Abstract
OBJECTIVE: The pathway by which herpes simplex virus 2 (HSV2) triggers the innate immune system in the urogenital system has not as yet been fully elucidated. In this study, we aimed to determine which pattern recognition receptors (PRRs) recognize HSV2 in primary vaginal epithelial cells. Once we deciphered the receptors involved, we aimed to target them to immunomodulate innate responses as a prophylactic or therapeutic intervention for early HSV2 infection. STUDY DESIGN: To determine which PRRs are involved, receptor silencing as well as confocal microscopy was utilized. For immunomodulation, PRR agonists were utilized to induce a strong, local response to limit the infection, and we used 2 quantitative methods, flow cytometry and plaque assays, to determine their effect on HSV2 replication. RESULTS: Our results show that HSV2 is detected by a plethora of PRRs: Toll-like receptors (TLR) 2 as well as deoxyribonucleic acid (DNA) sensors TLR9, DNA-dependent activator of interferon regulatory factors, and to a lesser extent interferon-inducible 16, which trigger cytokine secretion to protect the host. Using PRR agonists, such as lipoproteins, CpG DNA, and cyclic dinucleotides, we could significantly limit HSV2 replication. CONCLUSION: Different PRRs are strategically placed in different cell locations to detect virus invasion. Use of agonists that target and activate these PRRs appeared to be effective in preventing primary HSV2 infection in vaginal cells and could provide new insights in defense against HSV2 urogenital infections.
OBJECTIVE: The pathway by which herpes simplex virus 2 (HSV2) triggers the innate immune system in the urogenital system has not as yet been fully elucidated. In this study, we aimed to determine which pattern recognition receptors (PRRs) recognize HSV2 in primary vaginal epithelial cells. Once we deciphered the receptors involved, we aimed to target them to immunomodulate innate responses as a prophylactic or therapeutic intervention for early HSV2 infection. STUDY DESIGN: To determine which PRRs are involved, receptor silencing as well as confocal microscopy was utilized. For immunomodulation, PRR agonists were utilized to induce a strong, local response to limit the infection, and we used 2 quantitative methods, flow cytometry and plaque assays, to determine their effect on HSV2 replication. RESULTS: Our results show that HSV2 is detected by a plethora of PRRs: Toll-like receptors (TLR) 2 as well as deoxyribonucleic acid (DNA) sensors TLR9, DNA-dependent activator of interferon regulatory factors, and to a lesser extent interferon-inducible 16, which trigger cytokine secretion to protect the host. Using PRR agonists, such as lipoproteins, CpG DNA, and cyclic dinucleotides, we could significantly limit HSV2 replication. CONCLUSION: Different PRRs are strategically placed in different cell locations to detect virus invasion. Use of agonists that target and activate these PRRs appeared to be effective in preventing primary HSV2 infection in vaginal cells and could provide new insights in defense against HSV2 urogenital infections.
Authors: Eduardo I Tognarelli; Tomás F Palomino; Nicolás Corrales; Susan M Bueno; Alexis M Kalergis; Pablo A González Journal: Front Cell Infect Microbiol Date: 2019-04-30 Impact factor: 5.293
Authors: Paula A Suazo; Francisco J Ibañez; Angello R Retamal-Díaz; Marysol V Paz-Fiblas; Susan M Bueno; Alexis M Kalergis; Pablo A González Journal: Mediators Inflamm Date: 2015-03-30 Impact factor: 4.711
Authors: Elisa Crisci; Rada Ellegård; Sofia Nyström; Elin Rondahl; Lena Serrander; Tomas Bergström; Christopher Sjöwall; Kristina Eriksson; Marie Larsson Journal: J Virol Date: 2016-04-29 Impact factor: 5.103
Authors: Svetlana V Kostyuk; Lev N Porokhovnik; Elizaveta S Ershova; Elena M Malinovskaya; Marina S Konkova; Larisa V Kameneva; Olga A Dolgikh; Vladimir P Veiko; Vladimir M Pisarev; Andrew V Martynov; Vasilina A Sergeeva; Andrew A Kaliyanov; Anton D Filev; Julia M Chudakova; Margarita S Abramova; Serguey I Kutsev; Vera L Izhevskaya; Nataliya N Veiko Journal: Oxid Med Cell Longev Date: 2018-03-20 Impact factor: 6.543